FBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Fortress Biotech has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Fortress Biotech Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Fortress Biotech did not have earnings to cover the interest expense. Fortress Biotech's debt to revenue ratio for the quarter that ended in Sep. 2024 was 1.22. As of today, Fortress Biotech's Altman Z-Score is -10.21.
For the Biotechnology subindustry, Fortress Biotech's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Financial Strength distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Fortress Biotech's Interest Expense for the months ended in Sep. 2024 was $-2.24 Mil. Its Operating Income for the months ended in Sep. 2024 was $-22.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $67.77 Mil.
Fortress Biotech's Interest Coverage for the quarter that ended in Sep. 2024 is
Fortress Biotech did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Fortress Biotech's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Sep. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (3.764 | + | 67.765) | / | 58.516 | |
= | 1.22 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Fortress Biotech has a Z-score of -10.21, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -10.21 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (NAS:FBIO) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Fortress Biotech has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Thank you for viewing the detailed overview of Fortress Biotech's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosenwald Lindsay A Md | director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 375 PARK AVE, NEW YORK NY 10152 |
Dov Klein | director | C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
Lucy Lu | director | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
David Jin | officer: Chief Financial Officer | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Robyn Hunter | officer: Chief Financial Officer | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Malcolm Hoenlein | director | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Jimmie Harvey | director | 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Michael S Weiss | director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN | 750 LEXINGTON AVE, NEW YORK NY 10022 |
Kevin Lorenz | director | C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606 |
George Avgerinos | officer: SVP, Biologics Operations | C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Kevin Horgan | other: Former Chief Medical Officer | C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540 |
David Jonathan Barrett | director | ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
From GuruFocus
By Marketwired • 07-25-2024
By Marketwired • 08-13-2024
By Marketwired • 07-05-2024
By GuruFocus News • 10-25-2024
By Marketwired • 09-26-2024
By PRNewswire • 12-04-2023
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.